The global clinical oncology next generation sequencing (NGS) market was valued at USD 477.16 million in 2024, with an anticipated CAGR of 16.58% over the forecast period from 2025 to 2034. This growth is being propelled by distinct segment-level dynamics across product types, end-user industries, and applications. Sequencing instruments remain the largest revenue-generating category, primarily due to their high upfront costs and ongoing demand for system upgrades that enhance throughput and accuracy. However, consumables are emerging as a high-growth segment, benefiting from recurring purchase requirements and increasing